Apimeds Pharmaceuticals expands AI Futures Lab program

Apimeds Pharmaceuticals (APUS) announced the expansion of the Apimeds AI Futures Lab program through a new collaboration with the University of Oregon’s Lundquist College of Business, starting with the Winter 2026 quarter. The initiative connects student teams with real-world biopharma business development projects. AI Futures Lab functions as both a discovery engine for potential therapeutic assets. Through this collaboration, University of Oregon students will engage directly with Apimeds mentors to evaluate early-stage or shelved pharmaceutical assets, conduct market and IP analysis, and identify opportunities to advance patient care through novel business strategies.